The biopharmaceutical industry witnessed significant innovation, with many new recombinant protein therapeutics receiving FDA approval. However, these therapies are often costly, emphasizing the need for greater efficiency and productivity.
SynWeave™ : Redefining Cell Line Development for Next-Generation Biologics
